A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

Open-label Phase II pilot of Cognitive Processing Therapy integrated with two MDMA-assisted psychotherapy sessions over a 2-month course in participants with PTSD (n=10).

Primary aims are to assess safety, tolerability, and preliminary clinical benefit; MDMA is hypothesised to reduce fear and increase emotional engagement to enhance CPT mechanisms.